Mumbai, Friday, January 16, 2026 – Cipla Limited (BSE: 500087 | NSE: CIPLA) shares were trading lower on Friday morning, extending weakness in early trade as investors tracked the company’s recent update on the supply status of Lanreotide Injection in the United States.
Stock Movement Today
Cipla’s stock was trading in the red during the morning session, reflecting selling pressure soon after market open. The decline comes a day after the company communicated that Lanreotide Injection, one of its leading products in the US market, will remain in limited supply following a temporary production pause at its overseas manufacturing partner’s facility, with re-supply expected in the first half of FY27.Business Context
Lanreotide Injection for the US market is manufactured by Pharmathen International S.A., the exclusive supplier to Cipla’s wholly owned US subsidiary. Production has been temporarily paused to support remediation activities at the manufacturing facility. Until manufacturing restarts, the product will continue to be available in limited quantities, subject to quality clearance.The company has stated that it is monitoring supply levels closely and expects re-supply to resume in H1 FY 2026–27.
Share Price Snapshot
At 09:49 AM IST on January 16, 2026, Cipla shares were trading at ₹1,383.00, down ₹51.50 or 3.59 percent from the previous close of ₹1,434.50. The stock opened at ₹1,379.00, touched an intraday high of ₹1,394.90, and slipped to a low of ₹1,367.20 during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.